Press Releases

Sunshine Heart Exercises $2 Million Milestone Advance From Silicon Valley Bank

Posted on

EDEN PRAIRIE, Minn., June 29, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (NASDAQ:SSH) announced today that it has exercised the right to borrow an additional $2 million under its existing loan and security agreement with Silicon Valley Bank. The right to borrow this second tranche was conditioned on the U.S. Food and Drug Administration granting […]

Read More

Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF™ US Pivotal Study for C-Pulse® Heart Assist System

Posted on

EDEN PRAIRIE, Minn., May 26, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) is pleased to announce that the US Food and Drug Administration (FDA) has approved the resumption of patient enrollment in its COUNTER HF US pivotal study for the C-Pulse Heart Assist System. As such, the Company has already begun the process to […]

Read More

Sunshine Heart Announces First Quarter 2015 Results and Provides Corporate Update

Posted on

EDEN PRAIRIE, Minn., May 5, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today its financial results and provided a corporate update for the first quarter of 2015. The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on its ongoing […]

Read More

Sunshine Heart to Release First Quarter 2015 Results on May 5, 2015

Posted on

EDEN PRAIRIE, Minn., April 28, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its first quarter 2015 results will be released on Tuesday, May 5, 2015, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will […]

Read More

Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse® Heart Assist System

Posted on

EDEN PRAIRIE, Minn., April 16, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the U.S. Food and Drug Administration (FDA) has reviewed the Company’s submission regarding the COUNTER HF’s U.S. pivotal study pause and requested minor protocol changes be submitted in order to receive approval to resume patient enrollment. The FDA did […]

Read More